News／Press Release

​Sep.06, 2022
Will exhibit at “JAPAN HEALTHCARE VENTURE SUMMIT 2022” on 12-14 October 2022.(Open Link) 

July.20, 2022
TAKC-02 Exploratory Clinical Study registered (jRCTs031220218). 
(The exploratory clinical study of the oligonucleotide drug for male patients with moderate asthma)

​Jan.11, 2022
Selected for the “Jury's Special Award” at the Japan Healthcare Venture Summit 2021 (JHVS2021), which is given to those who have a particularly high possibility of practical application and potential of seeds.
The exhibitor pitch was held by the Ministry of Health, Labor and Welfare on 13-15 October 2021.(Open Link. Japanese release only)

May.19, 2022
Completed the Phase I Clinical Study of TAKC-02 (NCT05018533)

Aug.17, 2021
Started enrollment of TAKC-02 Phase I Clinical Study (NCT05018533). ​

Aug.10, 2021
​Exhibited at “JAPAN HEALTHCARE VENTURE SUMMIT 2021” on 13-15 October 2021.

​Mar.29,2021
Nippon Shokubai Co., Ltd. has released a press release regarding the Completion of GMP Manufacturing for Oligonucleotide API. (Open Link)​

Sep.10, 2019
​TAK-Circulator Announces to Collaborate on Development of TAKC-02 and Expand a Capital Alliance with Nippon Shokubai Co .,ltd through Third Party Allotment（Open Link）

Aug.02, 2016
​TAK-Circulator Announces to Form a Capital Alliance with Nippon Shokubai Co.,ltd. （Open Link）